學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
內容大綱
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the decision by the same company to let an option to acquire the company lapse. In a difficult capital market, the company had begun a reboot, but needed to figure out how to weave together key corporate development threads. New CEO and returning Constellation team member Jigar Raythatha wondered if Constellation could capitalize on the current portfolio and make the run to be a fully-integrated biopharmaceutical company selling its own products in the United States. He realized it would take a combination of clear goal setting, capital markets, and potentially partnering to balance this goal and returns for longtime shareholders. His background and training provide a playbook that might not apply-Constellation might not be able to secure another big pharma partnership and might instead need to put together a series of deals to secure needed capital and capabilities without trading away too much of the company's future.